In setting the stage for that work, we consider it irrefutable that transformative changes in cancer treatment have occurred due to the use of small-molecule inhibitors that target specific protein kinases and specific facets of apoptosis, angiogenesis, and immune checkpoint regulation [34,45,46]. The gene discussed is WEE1; the disease is cancer.